Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Want a no-equipment abs exercise that can be done anywhere—but *so over* basic crunches? Enter: the V-up. Also known as a jackknife, the bodyweight move recruits the entire core and provides a ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

随着FDA批准的ADC药物越来越多，受到鼓舞的开发商们明显地加大了对ADC管线资产的投资力度。ADC正在重新定义靶向癌症治疗的前景。ADC的发展，在抗体、有效载荷和接头的开发设计方面都实现了迭代更新。自从2000年首款ADC药物Mylotarg(ge ...

Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...

1Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas. *Corresponding Author: David E. Gerber, Division of Hematology-Oncology, Harold C. Simmons Comprehensive ...

Protein degrader drugs harness the natural protein-denaturing machinery in cells to remove rogue proteins associated with disease, and have been proposed as a way to address a wide range of ...

After hours: March 14 at 4:05:07 PM EDT Loading Chart for ANL ...

COPENHAGEN, Denmark I March 17, 2025 I Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart ...